Morgan Monslow | Principal Scientist, Discovery-Biology (ID-Vaccines),
Merck & Co., Inc.

Morgan Monslow, PhD, is a principal scientist in the department of Infectious Diseases and Vaccines at Merck in West Point, PA. In her current role, she supports Merck’s early vaccine development efforts and specializes in vaccine immunology. Before joining Merck, she received her PhD in molecular biology and microbiology from Case Western Reserve University in Cleveland, OH and completed her postdoctoral work at the University of Pennsylvania in Philadelphia, PA.

Appearances:

Day 1 - November 28 @ 14:05

Understanding the immunogenicity of a 21-valent pneumococcal conjugate vaccine

Morgan Monslow, Principal Scientist, Discovery-Biology (ID-Vaccines),, Merck & Co., Inc.

Day 1 - November 28 @ 16:50

Panel: Beyond PCV13: Exploring the Future of Pneumococcal Disease Vaccines

The current state of pneumococcal disease vaccine development and the limitations of PCV13.
New approaches to vaccine development, such as protein-based vaccines, conjugate vaccines, and combination vaccines
The potential impact of new vaccines on disease prevention and public health
Case for maternal immunization?
Challenges and opportunities for vaccine development in low- and middle-income countries

Moderator: Niranjan Kumar, President & Chief Executive Officer, ABS Inc. USA